Flexion Therapeutics Inc (FLXN): Samuel D Colella , director 10% owner of Flexion Therapeutics Inc purchased 25,504 shares on Jun 20, 2016. The Insider buying transaction was reported by the company on Jun 22, 2016 to the Securities and Exchange Commission. The shares were purchased at $13.74 per share for a total value of $349,599.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 16, 2016, C Ann Merrifield (director) purchased 1,000 shares at $13.39 per share price.On Jun 10, 2016, Samuel D Colella (director 10% owner) purchased 714,285 shares at $14.00 per share price.Also, On May 23, 2016, Michael D. Clayman (CEO) purchased 2,000 shares at $10.40 per share price.On May 20, 2016, Neil Bodick (Chief Medical Officer) purchased 850 shares at $10.00 per share price.
Flexion Therapeutics Inc: On Monday, Jun 20, 2016 heightened volatility was witnessed in Flexion Therapeutics Inc which led to swings in the share price. The shares opened for trading at $13.65 and hit $14.35 on the upside , eventually ending the session at $14.02, with a gain of 5.57% or 0.74 points. The heightened volatility saw the trading volume jump to 3,49,819 shares. The 52-week high of the share price is $29.09 and the company has a market cap of $302 M . The 52-week low of the share price is at $7.56.
Company has been under the radar of several Street Analysts.Flexion Therapeutics Inc is Resumed by Wells Fargo to Outperform. The Rating was issued on May 3, 2016.
Flexion Therapeutics Inc. is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is also focused on anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions such as osteoarthritis (OA) a type of degenerative arthritis. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum from moderate to severe pain. The Company’s products include FX006 which is indicated for front line intra-articular (IA) therapy for patients with moderate to severe OA pain; FX007 which is indicated for post-operative pain and FX005 which is indicated for end-stage OA pain. The Company is conducting a pivotal Phase IIb clinical trial of FX006. The Company is conducting preclinical local pharmacology and toxicology experiments of FX007. FX005 has completed its Phase IIa trials.